[{"_id":"project:357","_type":"project","abstract":{"sv":"Syfte och mål:  Avancerade terapier baserade på gener, celler eller vävnader (ATMP), har stor potential att generera helt nya sätt att behandla sjukdomar, t.o.m. stoppa, backa eller bota. Centre for Advanced Medical Products (CAMP) fokuserar på den vetenskap, teknik och infrastruktur som krävs för att implementera ATMP från laboratorium till klinisk praktik. Centret tar sig också an de system och organisatoriska utmaningar som har identifierats som hinder för utvecklingen av ATMP-fältet i Sverige.    Förväntade effekter och resultat:  Integrering av prekliniska, kliniska, tekniska och andra vetenskapliga områden, med kommersialiseringskompetenser, kommer att påskynda forskningsimplementering, nya patientbehandlingar och industriell tillväxt. Projektet kommer att optimera samarbetet mellan såväl ATMP-infrastrukturer och aktiviteter inom akademi/hälsovård som kommersiell preklinisk och klinisk FoU. Detta kommer att underlätta vidareutveckling och kommersialisering av ATMP och öka Sveriges konkurrenskraft inom detta område.    Upplägg och genomförande:  Forsknings- och innovationsprojekt som fokuserar på tekniskt kritiska aspekter av utveckling och produktion av ATMP kommer att utföras parallellt med att adressera utmaningar som identifierats som hinder eller förutsättningar för utveckling av fältet. Denna kombinerade metod kommer att koppla ihop akademisk, klinisk och industriell forskning och utveckling i Sverige. Inom perioden 2018-2023 kommer CAMP att etableras som ett internationellt erkänt centrum för FoU av ATMP.","en":"Purpose and goal:  Advanced therapies based on genes, cells or tissues (ATMP), have a great potential to generate completely new ways to treat patients; even to stop, reverse or cure diseases and injuries. Centre for Advanced Medical Products (CAMP) focuses on the science, technology and infrastructure required to translate ATMP from laboratory to clinical practice. The Centre also addresses systems and organisational challenges which have been identified as hurdles for development of the ATMP field in Sweden.    Expected results and effects:  Integration of pre-clinical, clinical, engineering and other scientific areas, with commercialisation competencies will accelerate research translation, enabling new patient treatments, and generate industrial growth. The project will optimise collaboration between ATMP infrastructures and activities in academia/healthcare and commercial pre-clinical and clinical R&D. This will facilitate further development and commercialisation of ATMP and thus increase Sweden’s competitiveness in this field.    Approach and implementation:  Research and innovation projects focusing on critical technological aspects of development and manufacturing of ATMP will run in parallel with Cross Cutting Priority challenges identified as important barriers or enablers for the development of the field. This combined approach will connect academic, clinical and industrial research and development in Sweden. Within the period 2018-2023, CAMP will be established as an internationally recognized centre for research and development of ATMP."},"project_id":"2017-02130_Vinnova","identifier_short":"2017-02130","dates":{"start_date":"2018-01-01","end_date":"2023-12-31"},"organizations":[{"funding":[{"_id":94,"id":"202100-5216","sv":"Vinnova","en":"Vinnova"}]},{"coordinating":[{"_id":715,"id":"202100-2874","sv":"Umeå universitet","en":"Umeå University"}]}],"people":[{"project_leaders":[{"_id":"authority-person:64033","orcid":"0000-0003-2596-5936","name":"Kingham, Paul J.","role":"principal_investigator","affiliation":[{"_id":734,"sv":"Institutionen för integrativ medicinsk biologi (IMB)","en":"Department of Integrative Medical Biology (IMB)","parent":[{"_id":716,"sv":"Medicinska fakulteten","en":"Faculty of Medicine","parent":[{"_id":715,"id":"202100-2874","sv":"Umeå universitet","en":"Umeå University"}]}]}]}]},{"other_personnel":[]}],"tags":[{"_id":11701,"id":"30401","sv":"Medicinsk bioteknologi (med inriktning mot cellbiologi (inklusive stamcellsbiologi), molekylärbiologi, mikrobiologi, biokemi eller biofarmaci)","en":"Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)"}],"titles":{"sv":"Centre for Advanced Medical Products","en":"Centre for Advanced Medical Products"},"total_funding":"48000000","type_of_awards":{"sv":"Projektbidrag","en":"Project grant"},"publications":[{"id":"diva2:2095238","type":"article-journal","status":"Published","issued":{"date-parts":[[2026]]},"title":"Extracellular vesicle secretome from mesenchymal stromal cells prevents post-ischemic heart failure by targeting cardiac fibrosis","language":"eng","author":[{"family":"Grinnemo","given":"Karl-Henrik","ORCID":"0000-0001-6717-3393","localId":"kargr698","affiliation":[{"name":"Uppsala Univ Hosp, Dept Cardiothorac Surg & Anesthesiol, Uppsala, Sweden"},{"id":"1352","name":"Uppsala universitet, Thoraxkirurgi"}]},{"family":"Braesch-Andersen","given":"Ken","localId":"kenbr185","affiliation":[{"id":"1352","name":"Uppsala universitet, Thoraxkirurgi"}]},{"family":"Wedin","given":"Johan","localId":"johwe950","affiliation":[{"id":"1352","name":"Uppsala universitet, Thoraxkirurgi"},{"name":"Uppsala Univ Hosp, Dept Cardiothorac Surg & Anesthesiol, Uppsala, Sweden"}]},{"family":"Velica","given":"Anna","ORCID":"0000-0002-4604-2949","localId":"annve628","affiliation":[{"id":"887402","name":"Uppsala universitet, Genomik och neurobiologi"}]},{"family":"Thelander","given":"Ulrika","ORCID":"0000-0002-6647-0967","localId":"ulrth444","affiliation":[{"name":"Uppsala Univ Hosp, Dept Pathol, Uppsala, Sweden"},{"id":"7706","name":"Uppsala universitet, Institutionen för immunologi, genetik och patologi"}]},{"family":"Sabatier","given":"Pierre","ORCID":"0000-0002-2734-1791","localId":"piesa271","affiliation":[{"name":"Univ Copenhagen, Novo Nord Fdn Ctr Prot Res, Fac Hlth & Med Sci, Dept Cellular & Mol Med, DK-2200 Copenhagen, Denmark"},{"id":"1352","name":"Uppsala universitet, Thoraxkirurgi"}]},{"family":"Beusch","given":"Christian M.","ORCID":"0000-0001-9100-8283","localId":"chrbe767","affiliation":[{"name":"Emory Univ, Sch Med, Dept Pathol & Lab Med, Pathol Adv Translat Res Unit PATRU, Atlanta, GA USA"},{"id":"1352","name":"Uppsala universitet, Thoraxkirurgi"}]},{"family":"Simonson","given":"Oscar","localId":"oscsi921","affiliation":[{"name":"Uppsala Univ Hosp, Dept Cardiothorac Surg & Anesthesiol, Uppsala, Sweden"},{"id":"1352","name":"Uppsala universitet, Thoraxkirurgi"}]},{"family":"Törne","given":"Alice","ORCID":"0009-0002-9886-2436","localId":"alito256","affiliation":[{"id":"1352","name":"Uppsala universitet, Thoraxkirurgi"}]},{"family":"Felldin","given":"Ulrika","ORCID":"0009-0001-9243-9111","localId":"ulrfe260","affiliation":[{"id":"1352","name":"Uppsala universitet, Thoraxkirurgi"}]},{"family":"Gritsenko","given":"Olga","localId":"olggr765","affiliation":[{"id":"1352","name":"Uppsala universitet, Thoraxkirurgi"}]},{"family":"Park","given":"Kyong-Su","affiliation":[{"name":"Univ Gothenburg, Inst Med, Sahlgrenska Acad, Krefting Res Ctr, Gothenburg, Sweden;"}]},{"family":"Crescitelli","given":"Rossella","affiliation":[{"name":"Univ Gothenburg, Sahlgrenska Acad, Sahlgrenska Ctr Canc Res, Dept Surg,Inst Clin Sci, Gothenburg, Sweden;"}]},{"family":"Ågren","given":"Nils","affiliation":[{"name":"Karolinska Inst, Dept Clin Sci Intervent & Technol, Div Transplantat Surg, Stockholm, Sweden;;Karolinska Univ Hosp, Dept Transplantat Surg, Huddinge, Sweden;"}]},{"family":"Meinke","given":"Stephan","affiliation":[{"name":"Karolinska Inst, Ctr Hematol & Regenerat Med HERM, Dept Med Huddinge, S-14152 Stockholm, Sweden;"}]},{"family":"Abouzayed","given":"Ayman","localId":"aymab857","affiliation":[{"id":"883700","name":"Uppsala universitet, Translationell avbildning med PET"},{"name":"Antaros TracerAB, Uppsala, Sweden"},{"id":"9051","name":"Uppsala universitet, Science for Life Laboratory, SciLifeLab"}]},{"family":"Wegrzyniak","given":"Olivia","ORCID":"0000-0001-9636-0390","localId":"oliwe969","affiliation":[{"id":"883700","name":"Uppsala universitet, Translationell avbildning med PET"},{"id":"9051","name":"Uppsala universitet, Science for Life Laboratory, SciLifeLab"}]},{"family":"Putri","given":"Andriana","ORCID":"0009-0001-6591-5098","localId":"putan351","affiliation":[{"id":"9051","name":"Uppsala universitet, Science for Life Laboratory, SciLifeLab"},{"id":"883700","name":"Uppsala universitet, Translationell avbildning med PET"}]},{"family":"Hedenqvist","given":"Patricia","affiliation":[{"name":"Swedish Univ Agr Sci, Dept Clin Sci, Uppsala, Sweden;"}]},{"family":"Rydén","given":"Anneli","affiliation":[{"name":"Swedish Univ Agr Sci, Dept Clin Sci, Uppsala, Sweden;"}]},{"family":"Leijon","given":"Alexandra","affiliation":[{"name":"Swedish Univ Agr Sci, Dept Clin Sci, Uppsala, Sweden;"}]},{"family":"Lindström","given":"Lisa","affiliation":[{"name":"Swedish Univ Agr Sci, Dept Anim Biosci, Uppsala, Sweden;"}]},{"family":"Velikyan","given":"Irina","ORCID":"0000-0002-3732-8857","localId":"irinveli","affiliation":[{"id":"9051","name":"Uppsala universitet, Science for Life Laboratory, SciLifeLab"},{"id":"883700","name":"Uppsala universitet, Translationell avbildning med PET"},{"name":"Uppsala Univ Hosp, PET Ctr, Uppsala, Sweden"}]},{"family":"Alici","given":"Evren","affiliation":[{"name":"Karolinska Inst, Ctr Hematol & Regenerat Med HERM, Dept Med Huddinge, S-14152 Stockholm, Sweden;"}]},{"family":"Wikström","given":"Johannes","affiliation":[{"name":"Ribocure Pharmaceut AB, Mölndal, Sweden;"}]},{"family":"Gan","given":"Li Ming","affiliation":[{"name":"Ribocure Pharmaceut AB, Mölndal, Sweden;;Suzhou Ribo Life Sci Co Ltd, Suzhou, Peoples R China;;Univ Gothenburg, Inst Med, Dept Cardiol, Dept Mol & Clin Med,Sahlgrenska Acad, Gothenburg, Sweden;"}]},{"family":"Lorant","given":"Tomas","ORCID":"0000-0002-2466-6259","localId":"tomalora","affiliation":[{"id":"1353","name":"Uppsala universitet, Transplantationskirurgi"}]},{"family":"Kumagai-Braesch","given":"Makiko","affiliation":[{"name":"Karolinska Inst, Dept Clin Sci Intervent & Technol, Div Transplantat Surg, Stockholm, Sweden;;Karolinska Univ Hosp, Dept Transplantat Surg, Huddinge, Sweden;"}]},{"family":"Ståhle","given":"Elisabeth","localId":"elsta102","affiliation":[{"name":"Uppsala Univ Hosp, Dept Cardiothorac Surg & Anesthesiol, Uppsala, Sweden"},{"id":"1352","name":"Uppsala universitet, Thoraxkirurgi"}]},{"family":"Korsgren","given":"Olle","ORCID":"0000-0002-8524-9547","localId":"ollekors","affiliation":[{"id":"887403","name":"Uppsala universitet, Cancerimmunterapi"},{"name":"Antaros TracerAB, Uppsala, Sweden;"}]},{"family":"Fromell","given":"Karin","ORCID":"0000-0001-8905-8791","localId":"kahul103","affiliation":[{"id":"887407","name":"Uppsala universitet, Vaskulärbiologi"}]},{"family":"Nilsson Ekdahl","given":"Kristina","ORCID":"0000-0001-7888-1571","localId":"krisnil","affiliation":[{"name":"Linnaeus Univ, Ctr Biomat Chem, Kalmar, Sweden"},{"id":"887407","name":"Uppsala universitet, Vaskulärbiologi"}]},{"family":"Nilsson","given":"Bo","ORCID":"0000-0003-0057-2730","localId":"bonils","affiliation":[{"id":"887407","name":"Uppsala universitet, Vaskulärbiologi"}]},{"family":"Lötvall","given":"Jan","affiliation":[{"name":"Univ Gothenburg, Inst Med, Sahlgrenska Acad, Krefting Res Ctr, Gothenburg, Sweden;"}]},{"family":"Jensen-Waern","given":"Marianne","affiliation":[{"name":"Swedish Univ Agr Sci, Dept Clin Sci, Uppsala, Sweden;"}]},{"family":"Olsen","given":"Jesper, V","affiliation":[{"name":"Univ Copenhagen, Novo Nord Fdn Ctr Prot Res, Fac Hlth & Med Sci, Dept Cellular & Mol Med, DK-2200 Copenhagen, Denmark;"}]},{"family":"Hagey","given":"Daniel W.","affiliation":[{"name":"Karolinska Inst, Dept Lab Med, Unit Biomol & Cellular Med, Stockholm, Sweden;;Karolinska Univ Hosp, Dept Cellular Therapy & Allogene Stem Cell Transpl, Huddinge, Sweden;"}]},{"family":"Andaloussi","given":"Samir E. L.","affiliation":[{"name":"Karolinska Inst, Dept Lab Med, Unit Biomol & Cellular Med, Stockholm, Sweden;;Karolinska Univ Hosp, Dept Cellular Therapy & Allogene Stem Cell Transpl, Huddinge, Sweden;;Karolinska ATMP Ctr, ANA Futura, Huddinge, Sweden;"}]},{"family":"Le Blanc","given":"Katarina","affiliation":[{"name":"Karolinska Univ Hosp, Dept Cellular Therapy & Allogene Stem Cell Transpl, Huddinge, Sweden;;Karolinska Inst, Dept Lab Med, Div Microbiol, Stockholm, Sweden;"}]},{"family":"James","given":"Stefan","ORCID":"0000-0003-4413-9736","localId":"stjam367","affiliation":[{"id":"11260","name":"Uppsala universitet, Kardiologi"},{"id":"1402","name":"Uppsala universitet, Uppsala kliniska forskningscentrum (UCR)"},{"name":"Uppsala Univ Hosp, Dept Clin Physiol & Cardiol, Uppsala, Sweden"}]},{"family":"Eriksson","given":"Olof","ORCID":"0000-0002-2515-8790","localId":"oloer586","affiliation":[{"id":"9051","name":"Uppsala universitet, Science for Life Laboratory, SciLifeLab"},{"id":"883700","name":"Uppsala universitet, Translationell avbildning med PET"},{"name":"Antaros TracerAB, Uppsala, Sweden"}]},{"family":"Rodin","given":"Sergey","ORCID":"0000-0002-6954-1986","localId":"serro142","affiliation":[{"id":"1352","name":"Uppsala universitet, Thoraxkirurgi"},{"name":"Uppsala Univ Hosp, Dept Cardiothorac Surg & Anesthesiol, Uppsala, Sweden"}]}],"abstract":"Myocardial ischemia-reperfusion (MIR) injury drives adverse remodeling and heart failure after ST-elevation myocardial infarction (STEMI), yet no therapy directly targets the fibrotic response. Here, we developed a good manufacturing practice-compatible extracellular vesicle (EV)-enriched secretome from bone marrow mesenchymal stromal cells and identified a laminin-521-based production strategy suitable for clinical translation. The EV-enriched secretome exhibited in vitro immunomodulatory activity, and in murine MIR-injury models, treatment preserved left ventricular ejection fraction, reduced platelet-derived growth factor receptor beta (PDGFR beta)-associated myofibroblast activation quantified by positron emission tomography (PET) imaging, attenuated fibrosis, and promoted reparative macrophage polarization. In a clinically relevant porcine ischemia-reperfus ion model, intracoronary administration was cardioprotective. We further developed a clinically approved PDGFR beta-targeted PET-imaging platform for longitudinal assessment of fibrotic activity in STEMI patients, where preliminary observations suggest that myofibroblast activation persists for up to 2 months after STEMI in selected patients. Together, these findings establish a translational therapeutic-diagnostic framework for individualized management of MIR injury.","DOI":"10.1016/j.stem.2026.07.003","PMID":"42497858","ScopusId":"2-s2.0-105046282744","NBN":"urn:nbn:se:uu:diva-596212","issue":"8","volume":"33","page":"1324-1338","container-title":"Cell Stem Cell","ISSN":"1875-9777","publisher":"Cell Press","note":"These authors contributed equally: Karl-Henrik Grinnemo, Sergey Rodin","published":[{"raw":"2026-08-25T14:34:39.110+02:00"}],"created":[{"raw":"2026-08-25T14:34:39.185+02:00"}],"updated":[{"raw":"2026-08-25T14:34:39.110+02:00"}],"URL":"https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-596212"},{"id":"diva2:1805949","type":"article-journal","status":"Published","issued":{"date-parts":[[2023]]},"title":"Patients accept therapy using embryonic stem cells for Parkinson's disease : a discrete choice experiment","language":"eng","author":[{"family":"Schölin Bywall","given":"Karin","ORCID":"0000-0002-5865-5590","localId":"karsc514","affiliation":[{"id":"1809","name":"Uppsala universitet, Centrum för forsknings- och bioetik"},{"name":"School of Health, Care and Social Welfare, Division of Health and Welfare Technology, Mälardalen University, Västerås, Sweden"}]},{"family":"Drevin","given":"Jennifer","ORCID":"0000-0003-4806-5471","localId":"jendr658","affiliation":[{"id":"1809","name":"Uppsala universitet, Centrum för forsknings- och bioetik"}]},{"family":"Groothuis-Oudshoorn","given":"Catharina"},{"family":"Veldwijk","given":"Jorien","ORCID":"0000-0003-4822-5068","localId":"jorve818","affiliation":[{"id":"1809","name":"Uppsala universitet, Centrum för forsknings- och bioetik"},{"name":"Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Erasmus Choice Modelling Centre, Erasmus University Rotterdam, Rotterdam, The Netherlands"}]},{"family":"Nyholm","given":"Dag","ORCID":"0000-0001-9776-7715","localId":"danyh856","affiliation":[{"id":"887057","name":"Uppsala universitet, Neurologi"}]},{"family":"Widner","given":"Hakan"},{"family":"van Vliet","given":"Trinette"},{"family":"Jiltsova","given":"Elena","localId":"eleji951","affiliation":[{"id":"887057","name":"Uppsala universitet, Neurologi"}]},{"family":"Hansson","given":"Mats","ORCID":"0000-0002-4053-8468","localId":"matshans","affiliation":[{"id":"1809","name":"Uppsala universitet, Centrum för forsknings- och bioetik"}]},{"family":"Viberg Johansson","given":"Jennifer","ORCID":"0000-0001-9533-9274","localId":"jenvi150","affiliation":[{"id":"1809","name":"Uppsala universitet, Centrum för forsknings- och bioetik"},{"name":"The Institute for Future Studies, Holländargatan 13, 111 36, Stockholm, Sweden"}]}],"abstract":"<b>Background:</b> New disease-modifying ways to treat Parkinson's disease (PD) may soon become a reality with intracerebral transplantation of cell products produced from human embryonic stem cells (hESCs). The aim of this study was to assess what factors influence preferences of patients with PD regarding stem-cell based therapies to treat PD in the future.<b>Methods:</b> Patients with PD were invited to complete a web-based discrete choice experiment to assess the importance of the following attributes: (i) type of treatment, (ii) aim of treatment, (iii) available knowledge of the different types of treatments, (iv) effect on symptoms, and (v) risk for severe side effects. Latent class conditional logistic regression models were used to determine preference estimates and heterogeneity in respondents' preferences.<b>Results:</b> A substantial difference in respondents' preferences was observed in three latent preference patterns (classes). \"Effect on symptoms\" was the most important attribute in class 1, closely followed by \"type of treatment,\" with medications as preferred to other treatment alternatives. Effect on symptoms was also the most important attribute in class 2, with treatment with hESCs preferred over other treatment alternatives. Likewise for class 3, that mainly focused on \"type of treatment\" in the decision-making. Respondents' class membership was influenced by their experience in treatment, side effects, and advanced treatment therapy as well as religious beliefs.<b>Conclusions:</b> Most of the respondents would accept a treatment with products emanating from hESCs, regardless of views on the moral status of embryos. Preferences of patients with PD may provide guidance in clinical decision-making regarding treatments deriving from stem cells.","DOI":"10.1186/s12910-023-00966-1","PMID":"37828462","ScopusId":"2-s2.0-85174217218","NBN":"urn:nbn:se:uu:diva-514599","issue":"1","volume":"24","number":"83","container-title":"BMC Medical Ethics","ISSN":"1472-6939","keyword":"Ethics; Human embryonic stem cells; Parkinson’s disease; Patient preferences","publisher":"BioMed Central (BMC)","published":[{"raw":"2023-10-19T10:05:00.000+02:00"}],"created":[{"raw":"2023-10-19T10:05:13.910+02:00"}],"updated":[{"raw":"2025-11-05T11:05:36.013+01:00"}],"URL":"https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-514599"}],"links":[{"type":"pid","link":"https://umu.diva-portal.org/smash/api/project/swecris/project:357"}]}]